Archer FusionPlex

Overview

Targeted RNA-based anchored multiplex PCR sequencing assay used to detect gene fusions, including partner-agnostic fusion calling.

PMID:37315267 — used to detect FOXO1 fusions (PAX3::FOXO1, PAX7::FOXO1) in extremity rhabdomyosarcoma, complementing FISH with custom BAC probes flanking FOXO1, PAX3, and PAX7 PMID:37315267.
PMID:37730754 — Archer FusionPlex used for FOXO1 fusion evaluation in the MSK FP-RMS cohort of relapsed/metastatic rhabdomyosarcoma (n=20); confirmed PAX3::FOXO1 and PAX7::FOXO1 status in fusion-positive cases PMID:37730754.
PMID:39753968 — MSK-Fusion (Archer FusionPlex) RNA-based fusion testing performed in 90 of 2,336 PDAC patients; identified activating MAPK-pathway fusions (e.g. GIT2-BRAF, ATP1B1-NRG1) nearly exclusive to KRAS-WT tumors (3.2% vs 0.04%, P=2×10⁻³⁵), directly informing classification of KRAS-WT and other-MAPK-mutant PDAC subtypes PMID:39753968.
Archer FusionPlex Anchored Multiplex PCR used in MSK-Solid Fusion panel to confirm rearrangements across 35 cancer-relevant genes in the 10,945-tumor MSK-IMPACT cohort PMID:28481359

85% of extremity ARMS cases in the cohort were FOXO1 fusion-positive; PAX3::FOXO1 had worse prognosis than PAX7::FOXO1 (HR 3.45, P=.016) PMID:37315267.

This page was processed by crosslinker on 2026-04-30. - PMID:28481359

This page was processed by wiki-cli on 2026-05-15.